Summary by Moomoo AI
On August 1, 2024, Pfizer Inc. reported the completion of a merger between Cerevel Therapeutics Holdings, Inc. and Symphony Harlan Merger Sub Inc., a subsidiary of AbbVie Inc. The merger resulted in Cerevel becoming a wholly owned subsidiary of AbbVie. At the effective time of the merger, each share of Cerevel's common stock was converted into the right to receive $45.00 per share in cash, excluding certain specified shares. This transaction was finalized as disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Following the merger, Cerevel's common stock ceased trading on The Nasdaq Capital Market and was delisted. Pfizer, which had beneficially owned shares in Cerevel, reported owning 0 shares post-merger, marking this filing as an 'exit filing' for the company.